Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2025-04-11 Share Issue/Capital Cha…
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Share Issue/Capital Change Classification · 82% confidence The document is a press release announcing two items: (1) the revocation of a Management Cease Trade Order following the filing of financial statements and related materials, and (2) the issuance of 1,200,000 common shares to settle debt. The key actionable item is the announcement of new share issuance as part of a debt settlement, which falls squarely under “Share Issue/Capital Change.” Although it references regulatory compliance, the primary corporate action is the capital change. Therefore, the appropriate classification is SHA.
2025-04-11 English
News release - English.pdf
Proxy Solicitation & Information Statement Classification · 97% confidence The document is a combined Notice of Annual Meeting and detailed Management Information Circular soliciting proxy votes for unitholders, including background on voting procedures, proposals (elect trustees, appoint auditors, advisory vote on compensation), corporate governance, executive compensation discussion, and related schedules. This matches the definition of a Proxy Solicitation & Information Statement (PSI), as it provides materials sent to unitholders to request votes for the meeting. It is not merely an announcement of a report, not an annual report itself, nor an earnings release. Therefore, the correct classification is PSI.
2025-04-02 English
News release - English.pdf
Capital/Financing Update Classification · 92% confidence The document is a press release announcing a debt settlement agreement by issuing common shares (1,200,000 shares at $0.05) to a lender to settle $60,000 of debt. This is a financing transaction and a change in capital structure. It is not an earnings release, management change, or AGM material, but clearly an update on financing activity. Therefore, it should be classified under Capital/Financing Update (CAP).
2025-04-02 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2025-03-31 English
Interim MD&A - English.pdf
Regulatory Filings
2025-03-31 English
Interim financial statements/report – English.pdf
Regulatory Filings
2025-03-31 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.